KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Idexx Laboratories (IDXX) over the last 16 years, with Sep 2025 value amounting to $488.9 million.

  • Idexx Laboratories' Accumulated Expenses fell 4.34% to $488.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $488.9 million, marking a year-over-year decrease of 4.34%. This contributed to the annual value of $502.1 million for FY2024, which is 4.89% up from last year.
  • Latest data reveals that Idexx Laboratories reported Accumulated Expenses of $488.9 million as of Q3 2025, which was up 17.24% from $417.0 million recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Accumulated Expenses ranged from a high of $541.1 million in Q2 2024 and a low of $366.9 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $466.3 million, with a median of $478.7 million in 2023.
  • As far as peak fluctuations go, Idexx Laboratories' Accumulated Expenses skyrocketed by 48.43% in 2021, and later decreased by 22.94% in 2025.
  • Over the past 5 years, Idexx Laboratories' Accumulated Expenses (Quarterly) stood at $458.9 million in 2021, then decreased by 5.50% to $433.7 million in 2022, then climbed by 10.39% to $478.7 million in 2023, then rose by 4.89% to $502.1 million in 2024, then declined by 4.34% to $488.9 million in 2025.
  • Its Accumulated Expenses stands at $488.9 million for Q3 2025, versus $417.0 million for Q2 2025 and $490.7 million for Q1 2025.